COMMUNIQUÉS West-GlobeNewswire
-
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation
07/07/2026 -
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
07/07/2026 -
Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1
07/07/2026 -
SPRINT® PNS Publication Highlights Sustained Benefits in Low Back Pain Patients
07/07/2026 -
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
07/07/2026 -
Press Release Biocartis NV: Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnostics
07/07/2026 -
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
07/07/2026 -
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
07/07/2026 -
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
07/07/2026 -
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
07/07/2026 -
Nu-Tek BioSciences Present Cell Nutrient Innovation, Raw Material Expertise at SIMB 2026
07/07/2026 -
SS Innovations Subsidiary SSICRS Graduates Inaugural Cardiac Robotic Surgery Training Class
07/07/2026 -
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
07/07/2026 -
Stipple Bio Appoints Biopharma Business Development Leader Roland Gendron as Chief Business Officer
07/07/2026 -
Transactions in connection with share buy-back program
07/07/2026 -
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
07/07/2026 -
ImageneBio Appoints Matt Robbins as General Counsel
07/07/2026 -
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
07/07/2026 -
ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs
07/07/2026
Pages